South Korea's Financial Supervisory Service (FSS) will release disclosure guidelines for pharmaceutical and biotech listed companies this month. The guidelines aim to address investor confusion caused by companies prioritizing press releases over official disclosures and emphasizing projected contract values rather than confirmed payments. The FSS completed task force meetings and consultations with KOSPI and KOSDAQ listed companies on the 19th before finalizing the recommendations, which will focus on three principles: disclosure priority, content consistency between press materials and official filings, and fair disclosure practices.
FSS Guidelines Establish Three Disclosure Principles
The FSS guidelines will operate as recommendations rather than legally binding requirements, according to the financial investment industry on the 19th. The FSS will not pursue separate disclosure form revisions. Companies will not face immediate sanctions solely for not following the guidelines. However, violations of existing regulations such as failure to comply with fair disclosure rules or false/omitted disclosures during actual information provision or disclosure processes can result in separate enforcement actions. The three core principles covered in the guidelines are disclosure priority over media coverage, consistency between press release content and official disclosures, and fair disclosure practices.
Technology Export Contracts Require Stage-by-Stage Milestone Breakdown
The guidelines will require companies to distinguish upfront contract payments from conditional milestone payments broken down by development stages including clinical trials, product approval, and commercialization. Previously, technology export contract disclosures included upfront payments and conditional milestones, but often did not clearly show how much would be received at each development stage. The FSS aims to help investors more easily understand whether contract amounts are confirmed and assess development stage risks and future timelines. Milestones in technology export contracts are conditional payments made when specific conditions are met, such as successful clinical trials, obtaining product approval, commercialization, or achieving sales targets. However, stage-by-stage amounts and payment conditions may constitute trade secrets for listed companies. During the consultation process, companies conveyed that uniform standards are difficult to apply because drug development stages and contract structures vary by company.
Samchundang Pharm Contract Disclosure Shows 5.3 Trillion KRW Gap
Samchundang Pharm presented approximately 5.3 trillion KRW as the total contract size in a press release regarding an exclusive license and commercialization contract for 11 European countries. In contrast, the exchange disclosure listed 30 million EUR, approximately 50.8 billion KRW at the exchange rate at the time, combining upfront payment and conditional milestones. The FSS identified this gap between contractual amounts and estimates based on future performance assumptions as creating investor misunderstanding, as companies did not clearly distinguish between the two in promotional materials. The guidelines seek to reduce the gap between media promotions and disclosure content by requiring companies to separate total contract amounts from confirmed upfront payments and show stage-specific milestones.
FAQ
What enforcement actions apply to companies that do not follow the FSS pharma disclosure guidelines?
The guidelines operate as recommendations, not legally binding requirements, and companies will not face immediate sanctions solely for not following them. However, violations of existing regulations such as failure to comply with fair disclosure rules or false/omitted disclosures can result in separate enforcement actions.
Why does the FSS require technology export contracts to show milestone payments by development stage?
The FSS aims to help investors more easily understand whether contract amounts are confirmed and assess development stage risks and future timelines. Previously, disclosures often did not clearly show how much would be received at each development stage, even though they included upfront payments and conditional milestones.
When will the FSS release the pharma and biotech disclosure guidelines?
The FSS will release the guidelines this month after completing task force meetings and consultations with KOSPI and KOSDAQ listed companies on the 19th.
